Table 3 Characteristics of 13,663 patients with a first-time hospital-based diagnosis of HZ, Denmark, 1994–2012
Characteristic | No. | Percent |
|---|---|---|
Age group (years)a | ||
0–9 | 492 | (3.6) |
10–19 | 368 | (2.7) |
20–29 | 623 | (4.6) |
30–39 | 772 | (5.7) |
40–49 | 885 | (6.5) |
50–59 | 1650 | (12) |
60–69 | 2357 | (17) |
70–79 | 3094 | (23) |
80–89 | 2859 | (21) |
≥ 90 | 563 | (4.1) |
Sex | ||
Women | 7823 | (57) |
Men | 5840 | (43) |
Any of the comorbidities identified | 8067 | (59) |
Charlson Comorbidity Index level | ||
None | 6058 | (44) |
Moderate | 2364 | (17) |
Severe | 2374 | (17) |
Very severe | 2867 | (21) |
Comorbidities in the Charlson Comorbidity Index | ||
Myocardial infarction | 921 | (6.7) |
Congestive heart failure | 1050 | (7.7) |
Peripheral vascular disease | 803 | (5.9) |
Cerebrovascular disease | 1446 | (11) |
Dementia | 256 | (1.9) |
Chronic pulmonary disease | 1911 | (14) |
Connective tissue disease | 983 | (7.2) |
Ulcer disease | 848 | (6.2) |
Mild liver disease | 171 | (1.3) |
Diabetes without end-organ damage | 918 | (6.7) |
Hemiplegia | 57 | (0.42) |
Moderate to severe renal disease | 643 | (4.7) |
Diabetes with end-organ damage | 419 | (3.1) |
Non-metastatic solid tumor | 1755 | (13) |
Leukemia | 489 | (3.6) |
Lymphoma | 834 | (6.1) |
Moderate to severe liver disease | 62 | (0.45) |
Metastatic solid tumor | 331 | (2.4) |
Acquired immune deficiency syndrome | 153 | (1.1) |
Comorbidities associated with immune dysregulation | 4942 | (36) |
Stem cell or bone marrow transplant | 273 | (2.0) |
Solid organ transplant | 152 | (1.1) |
Human immunodeficiency virus infection | 210 | (1.5) |
Primary immunodeficiency | 61 | (0.45) |
Any cancer | 2821 | (21) |
Any autoimmune disease | 2293 | (17) |
Hematologic | 73 | (0.53) |
Endocrine | 614 | (4.5) |
Central nervous system | 67 | (0.49) |
Gastrointestinal | 274 | (2.0) |
Skin | 315 | (2.3) |
Connective tissue disease | 1080 | (7.9) |
Pulmonary | 31 | (0.23) |
Ocular | 94 | (0.69) |